Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

1 hour ago 2

Cory Renauer, The Motley Fool

Sat, May 16, 2026 astatine 10:01 AM CDT 4 min read

What happened

According to an SEC filing dated May 15, 2026, Acuta Capital Partners, LLC initiated a caller presumption successful Erasca (NASDAQ:ERAS) during the archetypal quarter. The money acquired 354,575 shares, with an estimated transaction worth of $4.19 cardinal based connected the mean closing terms for the period. The quarter-end worth of the involvement roseate to $5.74 million, a alteration reflecting some the stock summation and terms fluctuations during the quarter.

What other to cognize

This was a caller presumption for the fund, representing 4.05% of reported U.S. equity holdings arsenic of March 31, 2026
Top holdings aft the filing:
- NASDAQ: PRAX: $27.35 cardinal (19.8% of AUM)
- NASDAQ: TERN: $26.14 cardinal (18.9% of AUM)
- NASDAQ: WHWK: $11.77 cardinal (8.5% of AUM)
- NASDAQ: TNGX: $9.24 cardinal (6.7% of AUM)
- NASDAQ: DRUG: $8.17 cardinal (5.9% of AUM)
As of May 14, 2026, Erasca shares were priced astatine $10.37, up 716.5% implicit the anterior year, delivering alpha of 689.24 percent points versus the S&P 500

Company Overview

Metric

Value

Price (as of marketplace adjacent 2026-05-15)	$10.23
Market capitalization	$3.15 billion
Net income (TTM)	$-277.02 million
One-year terms change	705.5%

Company Snapshot

Develops and advances targeted therapies for RAS/MAPK pathway-driven cancers, with pb objective candidates including ERAS-007 (oral ERK1/2 inhibitor), ERAS-601 (oral SHP2 inhibitor), and ERAS-801 (CNS-penetrant EGFR inhibitor).
Operates arsenic a clinical-stage biopharmaceutical institution focused connected the improvement and aboriginal commercialization of proprietary oncology therapeutics.
Targets patients with difficult-to-treat cancers specified arsenic non-small compartment lung cancer, colorectal cancer, acute myeloid leukemia, and recurrent glioblastoma multiforme.

Erasca, Inc. is simply a biotechnology institution headquartered successful San Diego, California, focused connected discovering and processing therapies for cancers driven by the RAS/MAPK pathway. The institution leverages a robust pipeline of oral targeted inhibitors, aiming to code important unmet aesculapian needs successful oncology. Its strategy centers connected advancing objective candidates with differentiated mechanisms of enactment to found a competitory borderline successful targeted crab therapeutics.

What this transaction means for investors

Acuta Capital’s caller Erasca presumption isn’t successful the firm’s apical five, but it’s a important bet. It was the seventh largest presumption retired of 27 astatine the extremity of March.

Hopefully, Acuta Capital exited its presumption successful April, earlier the banal collapsed. The banal is down by much than fractional from the highest it acceptable successful April.

On April 27, the institution reported signifier 1 proceedings results for ERAS-0015, a crab attraction campaigner it describes arsenic pan-RAS molecular glue. The company’s experimental treatments are designed to unopen down the RAS/MAPK pathway, which is implicated successful the spreading of coagulated tumors.

Read Entire Article